Skip to search formSkip to main contentSkip to account menu

LB 30057

Known as: LB-30057, LB30057 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzamides
CI-1028

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
LB30057, a Direct Thrombin Inhibitor, the Effect of Restenosis in Porcine Coronary Injury Model
Background and Objectives:In a previous study, LB30057 was found to inhibit smooth muscle cell proliferation in a dose dependent… 
2003
2003
LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in Rats and Dogs
The anti-thrombotic effects of LB30057, a direct thrombin inhibitor, were evaluated with in vivo rat and dog thrombosis models… 
2002
2002
Lb30057 inhibits platelet aggregation and vascular relaxation induced by thrombin
Previous study showed that an amidrazonophenylalanine derivative, LB30057, which has high water solubility, inhibited the… 
2001
2001
Antithrombotic Effect of LB-30057 (CI-1028), a New Synthetic Thrombin Inhibitor, in a Rabbit Model of Thrombosis: Comparison with Inogatran
LB-30057 (CI-1028) is a novel, orally bioavailable, direct thrombin inhibitor with a Ki of 0.38[emsp4 ]nM against human thrombin… 
1999
1999
Fluorobenzamidrazone thrombin inhibitors: influence of fluorine on enhancing oral absorption.
1998
1998
Structural modification of an orally active thrombin inhibitor, LB30057: replacement of the D-pocket-binding naphthyl moiety.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)